Encellin, a personalized regenerative medicine biotech company, founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.
